Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Cytosorbents Co. (NASDAQ:CTSO) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. StockNews.com began coverage on Cytosorbents in a report on Tuesday. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

The company has a market cap of $61.79 million, a P/E ratio of -3.14 and a beta of 0.78. The stock’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.05. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares during the period. Skylands Capital LLC raised its holdings in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Cytosorbents during the 4th quarter valued at $99,000. Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares in the last quarter. Finally, Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.